BREAST, cilt.25, ss.22-26, 2016 (SCI-Expanded)
Purpose: The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab.